Currently, two DNA methylation biomarkers for colorectal cancer (CRC) have been approved by the FDA: SEPT9, utilized in blood screening tests, and a combination of NDRG4 and BMP3 for stool tests [7]. Here, NDRG4 is linked to colorectal carcinoma.